Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice

Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice

Aim. To determine lenvatinib treatment outcomes in patients with advanced unresectable hepatocellular carcinoma (uHCC) in real clinical practice.Patients and methods. A multicenter retrospective observational study included 58 patients with a confirmed uHCC diagnosis receiving lenvatinib. At baselin...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. V. Petkau, A. V. Sultanbaev, K. V. Menshikov, A. S. Antipin, M. V. Volkonsky, V. M. Filippova, Yu. V. Vasilyeva, A. A. Tarkhanov, M. R. Mukhitova, M. Zh. Murzalina, A. R. Safarova
Format:	Article
Language:	Russian
Published:	Gastro LLC 2022-12-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	liver cancer hepatocellular carcinoma hcc targeted therapy lenvatinib real clinical practice
Online Access:	https://www.gastro-j.ru/jour/article/view/723
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis
by: Lingling Zhao, et al.
Published: (2025-02-01)

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors
by: Xin Y, et al.
Published: (2025-01-01)

Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
by: Hironori Ochi, et al.
Published: (2025-01-01)

Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus
by: Li X, et al.
Published: (2025-01-01)

Liver Transplantation in the Treatment of Unresectable Hepatocellular Carcinoma in the Absence of Liver Cirrhosis
by: O. D. Olisov, et al.
Published: (2018-09-01)

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
by: Masaud Shah, et al.
Published: (2025-01-01)

Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib
by: Naoki Fukuda, et al.
Published: (2024-04-01)

The miRNA‐mRNA Regulatory Network in Human Hepatocellular Carcinoma by Transcriptomic Analysis From GEO
by: Razieh Heidari, et al.
Published: (2025-01-01)

CircUCK2(2,3) promotes cancer progression and enhances synergistic cytotoxicity of lenvatinib with EGFR inhibitors via activating CNIH4–TGFα–EGFR signaling
by: Xindong Wei, et al.
Published: (2025-01-01)

Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases—meta‐analytic assessment
by: Kazuo Tarao, et al.
Published: (2019-03-01)

The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
by: Wu Y, et al.
Published: (2025-02-01)

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver
by: Indra Radek, et al.
Published: (2024-09-01)

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
by: Hongjie Cai, et al.
Published: (2025-02-01)

Research of <i>PNPLA3</i> I148M Gene Polymorphism in Patients with Non-Alcoholic Fatty Liver Disease, with Liver Cirrhosis and with Hepatocellular Carcinoma
by: V. V. Petkau, et al.
Published: (2023-11-01)

Metabolic reprogramming of glucose: the metabolic basis for the occurrence and development of hepatocellular carcinoma
by: Kai Wang, et al.
Published: (2025-02-01)

PIVKA-II as a surrogate biomarker for therapeutic response in Non-AFP-secreting hepatocellular carcinoma
by: San-Chi Chen, et al.
Published: (2025-02-01)

Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States
by: Finn RS, et al.
Published: (2025-02-01)

Risk factors of development of hepatocellular carcinoma
by: V. T. Ivashkin, et al.
Published: (2009-02-01)

TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
by: Wang W, et al.
Published: (2025-01-01)

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
by: Su H, et al.
Published: (2025-02-01)

Gut Microbiome Modulation in Hepatocellular Carcinoma: Preventive Role in NAFLD/NASH Progression and Potential Applications in Immunotherapy-Based Strategies
by: Elisa Monti, et al.
Published: (2025-01-01)

PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study
by: He Z, et al.
Published: (2025-01-01)

DNA methylation of ACADS promotes immunogenic cell death in hepatocellular carcinoma
by: Ze Qian, et al.
Published: (2025-01-01)

Screening and Early Diagnosis of Hepatocellular Cancer and Optimization of Diagnostic Imaging Techniques: A Review and Conclusion of the Expert Panel
by: V. V. Breder, et al.
Published: (2023-02-01)

TREM2 promotes the formation of a tumor-supportive microenvironment in hepatocellular carcinoma
by: Hanrui Guo, et al.
Published: (2025-01-01)

Structure of Patients with Hepatocellular Cancer (Data Analysis from Two Specialised Centres)
by: M. V. Mayevskaya, et al.
Published: (2020-05-01)

The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy
by: Tian He, et al.
Published: (2025-01-01)

Exploration of the mechanism of 5-Methylcytosine promoting the progression of hepatocellular carcinoma
by: Qiyao Zhang, et al.
Published: (2025-02-01)

TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis
by: Jin Li, et al.
Published: (2025-01-01)

Development of a genetically tailored implantation hepatocellular carcinoma model in Oncopigs by somatic cell CRISPR editing
by: Lobna Elkhadragy, et al.
Published: (2025-01-01)

A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy
by: Hiroyuki Iwasaki, et al.
Published: (2020-01-01)

Identification of MORF4L1 as an endogenous substrate of CRBN and its potential role as a therapeutic target in cancer
by: Luyao Zhang, et al.
Published: (2025-01-01)

Essential oils from Amorpha fruticosa against hepatocellular carcinoma based on network pharmacology
by: Yixian Liu, et al.
Published: (2025-01-01)

Nanoformulation of Spirooxindole and Methods for Treating Hepatocellular Carcinoma
by: Assem Barakat, et al.
Published: (2025-01-01)

Short Telomere Length in Plasma of Sudanese Patients with Hepatocellular Carcinoma and Chronic Liver Diseases
by: Fayza A. Rahamtalla, et al.
Published: (2024-12-01)

Pathology and diagnostic approaches to well-differentiated hepatocellular lesions: a narrative review
by: Joon Hyuk Choi, et al.
Published: (2025-01-01)

Genetic polymorphism of hepatitis C virus and risk of hepatocellular carcinoma
by: S. N. Mammayev, et al.
Published: (2014-09-01)

Hsp90α promotes lipogenesis by stabilizing FASN and promoting FASN transcription via LXRα in hepatocellular carcinoma
by: Zihao Deng, et al.
Published: (2025-01-01)